Literature DB >> 12773748

Management of high-risk populations with locally advanced prostate cancer.

Masood A Khan1, Alan W Partin.   

Abstract

Prostate cancer that extends beyond the confines of the prostatic gland on clinical and/or radiographic assessment, without evidence of lymph node or distant metastases, is regarded as locally advanced. The locally advanced prostate cancer patient population consists of a heterogeneous group of men, some of whom have tumors that may be amenable to primary curative intent with local definitive therapy associated with acceptable long-term cancer control rates. In order to optimally manage this group of patients, it is important to be able to recognize who is at a high risk of tumor recurrence after primary local therapy. In this brief review, we discuss the factors that contribute to the prediction of high risk in populations with locally advanced disease and the treatment options available.

Entities:  

Mesh:

Year:  2003        PMID: 12773748     DOI: 10.1634/theoncologist.8-3-259

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  5 in total

Review 1.  [Treatment of locally advanced prostate cancer].

Authors:  M P Wirth; O W Hakenberg; M Fröhner
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

Review 2.  Optimal treatment of locally advanced prostate cancer.

Authors:  Manfred P Wirth; Oliver W Hakenberg; Michael Froehner
Journal:  World J Urol       Date:  2007-02-27       Impact factor: 4.226

3.  [Is there an indication for adjuvant or neoadjuvant systemic therapy in prostate cancer?].

Authors:  C Börgermann; K Miller; F vom Dorp; T Jäger; H Rübben
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

4.  Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.

Authors:  Gincy George; Lucie-Marie Scailteux; Hans Garmo; Frédéric Balusson; Christopher Cardwell; Greet De Coster; Harlinde De Schutter; Josephina G Kuiper; Úna McMenamin; Julie Verbeeck; Mieke Van Hemelrijck
Journal:  Fundam Clin Pharmacol       Date:  2019-03-25       Impact factor: 2.748

5.  Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management.

Authors:  Petros Sountoulides; Thomas Rountos
Journal:  ISRN Urol       Date:  2013-07-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.